Akebia therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass. , july 1, 2024 /prnewswire/ -- akebia therapeutics®, inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 517,000 shares of akebia's common stock on june 28, 2024, including an option to purchase 500,000 shares to erik ostrowski, akebia's newly hired chief financial officer and chief business officer.
NDAQ Ratings Summary
NDAQ Quant Ranking